Familial Mediterranean fever gene (MEFV) mutations and disease severity in systemic lupus erythematosus (SLE): implications for the role of the E148Q MEFV allele in inflammation

Abstract

Objective

Observed low prevalence of SLE among familial Mediterranean fever (FMF) patients in several large cohorts suggests a possible protective effect of the MEFV mutations from SLE. In contrast, SLE patient carriers for the common MEFV mutations had rather complex disease expression with an increased frequency of febrile episodes and pleurisy and a decreased renal complication rate. Our aim was to investigate the prevalence of MEFV gene mutations in patients with SLE and their effect on organ involvement in a well-defined group of biopsy-proven SLE nephritis patients.

Material and method

The prevalence of four MEFV gene mutations (M694V, M680I, V726A and E148Q) was investigated in 114 SLE patients and effect on disease severity was analyzed in patients with biopsy-proven SLE nephritis.

Results

None of the SLE patients fulfilled the revised Tel-Hashomer criteria. Fourteen of 114 SLE patients (12.2%) were found to carry at least one MEFV mutation. A single patient in the SLE-Nephritis group was compound heterozygous for M694V/M680I mutations and only one patient in the SLE-Mild group was homozygous for E148Q mutation. Carrier frequency was similar to controls in SLE patients (12.2 vs 18.8%, p = 0.34). After the exclusion of the less penetrant E148Q mutation, re-analysis revealed an association between exon 10 mutations and SLE nephritis (p = 0.050, odds ratio (OR) = 4.16, 95% confidence interval (CI) = 1.04–16.6). Carrier rate for the E148Q mutation decreased in the SLE group (controls vs. SLE = 20/186 vs. 3/114, p = 0.08) and E148Q mutation was absent in SLE nephritis (controls vs. SLE nephritis = 20/186 vs. 0/47, p = 0.016, OR = 11.69, 95% CI = 0.69–197.13).

Conclusions

Carrier rate for the studied MEFV mutations was slightly lower in the SLE group, which is in agreement with previous observations that FMF may confer some protection from SLE. Exon 10 mutations were associated with SLE nephritis after the exclusion of the E148Q mutation. The significance of the E148Q as a disease-causing mutation is controversial, and whether E148Q substitution is a polymorphism generally affecting inflammatory pathways is not addressed in the current literature.

In this regard, absence of the E148Q mutation in SLE nephritis may serve as a clue for further investigation into its role as a general modulatory polymorphism for inflammation. This clarification is necessary to conclude whether other more penetrant MEFV gene mutations confer susceptibility to nephritis in SLE.

Keywords

MEFV E148Q SLE disease severity

Get full access to this article

View all access options for this article.

References

French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25–31.

Eisenberg

Aksentijevich

Deng

Kastner

Matzner

. Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med 1998; 129: 539–542.

Masters

Simon

Aksentijevich

Kastner

. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009; 27: 621–668.

Lachmann

Sengul

Yavuzsen

. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746–750.

Cosan

Ustek

Oku

. Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum 2010; 62: 3232–3236.

Ozcakar

Yalcinkaya

Cakar

. MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 2008; 35: 2427–2429.

Yalcinkaya

Ozcakar

Kasapcopur

. Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. J Pediatr 2007; 151: 675–678.

Rabinovich

Livneh

Langevitz

. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 2005; 64: 1009–1014.

Fidder

Chowers

Ackerman

. The familial Mediterranean fever (MEVF) gene as a modifier of Crohn’s disease. Am J Gastroenterol 2005; 100: 338–343.

10.

Atagunduz

Ergun

Direskeneli

. MEFV mutations are increased in Behcet’s disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21: 35–37.

11.

Padeh

Stoffman

Berkun

. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J 2008; 10: 358–360.

12.

Gershoni-Baruch

Shinawi

Leah

Badarnah

Brik

. Familial Mediterranean fever: Prevalence, penetrance and genetic drift. Eur J Hum Genet 2001; 9: 634–637.

13.

Yilmaz

Ozen

Balci

. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001; 9: 553–555.

14.

Akar S, Solmaz D, Onen F, et al. E148Q is not a disease causing allele in familial Mediterranean fever: Meta-analysis of the published studies in Turkish population [abstract]. 2011 EULAR abstract book.

15.

Erer

Cosan

Oku

. MEFV gene variations in patients with systemic lupus erythematosus. Mod Rheumatol 2014; 24: 93–96.

16.

Shinar

Kosach

Langevitz

. Familial Mediterranean FeVer gene (MEFV) mutations as a modifier of systemic lupus erythematosus. Lupus 2012; 21: 993–998.

17.

Ozen

Bakkaloglu

. C reactive protein: Protecting from lupus in familial Mediterranean fever. Ann Rheum Dis 2005; 64: 786–787.

18.

Kontaki

Boumpas

. Innate immunity in systemic lupus erythematosus: Sensing endogenous nucleic acids. J Autoimmun 2010; 35: 206–211.

19.

Tan

Cohen

Fries

. 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

20.

Livneh

Langevitz

Zemer

. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879–1885.

21.

Lidar

Zandman-Goddard

Shinar

Zaks

Livneh

Langevitz

. Systemic lupus erythematosus and familial Mediterranean fever: A possible negative association between the two disease entities – report of four cases and review of the literature. Lupus 2008; 17: 663–669.

22.

Ben-Chetrit

Lerer

Malamud

Domingo

Abeliovich

. The E148Q mutation in the MEFV gene: Is it a disease-causing mutation or a sequence variant? Hum Mutat 2000; 15: 385–386.

23.

Tchernitchko

Legendre

Cazeneuve

Delahaye

Niel

Amselem

. The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever. Hum Mutat 2003; 22: 339–340.

24.

Lidar

Shinar

Goldberg

Ben-Zvi

Langevitz

Livneh

. E148Q MEFV mutation carriage and longevity in individuals of Ashkenazi origin. Immunol Res 2013; 56: 371–375.

25.

Richards

Schaner

Diaz

. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001; 276: 39320–39329.

26.

Hornung

Latz

. Intracellular DNA recognition. Nat Rev Immunol 2010; 10: 123–130.

27.

Knight

Kaplan

. Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr Opin Rheumatol 2012; 24: 441–450.

28.

Kahlenberg

Carmona-Rivera

Smith

Kaplan

. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013; 190: 1217–1226.

29.

Hakkim

Fürnrohr

Amann

. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010; 107: 9813–9818.

30.

Yang

. Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus. J Rheumatol 2014; 41: 444–452.